☆
Watchlist
Log in
Sign-up
Avecho Biotechnology Ltd (ave) Logo

Avecho Biotechnology Ltd (AVE)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

AVE Chart

Snapshot

AVE's Principal Activity is the development, production, sale and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skin care and animal health and nutrition industries.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) +13.31%
vs ASX 200 (1yr) +6.11%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,556 of 2,417
Sector Rank 136 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies HMD / AHC / BDA
EPS -$0.002
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

AVE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Avecho Biotechnology Limited (AVE, formerly Phosphagenics Limited) is into developing and commercialising products containing its TPM technology. Each of the business divisions, Production, Human Health, and Animal Health and Nutrition have progressed with the common goal of advancing commercialisation of products containing the Company's TPM technology.

Incorporation Details

Incorporated in VIC on 19/06/1992 as Greenchip Development Capital Ltd. Name changed to Vital Capital Limited on 27/04/1999. Name changed to Phosphagenics Limited on 10/2/2004. Changed GICS from 4020 Diversified Financials to 3520 Pharmaceuticals & Biotechnology on 4/3/2005.

Corporate Details

Head Office Clayton VIC 3168
Website www.avecho.com.au
Registry Computershare
Auditor Grant Thornton Audit Pty Ltd
Date Listed 11 Aug 1993

Upcoming Calendar (Forecasted)

Date Event
23/08/2022 Report (Interim)
27/02/2023 Report (Prelim)
27/02/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
22/09/2010 $0.03 0% $0.03 Final 21/10/2010
26/02/2010 $0.02 0% $0.02 Interim 24/03/2010
30/09/2009 $0.02 0% $0.02 Final 21/10/2009
26/02/2009 $0.02 0% $0.02 Interim 31/03/2009

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.00
Gross DPS(TTM) $0.00
Dividend yield
Gross yield
Payout Ratio --
DRP No
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Dr Paul Gavin Chief Executive Officer May 2020
Mr Matthew Patrick McNamara Non-Executive Director Jan 2020

Mr Matthew Patrick McNamara

Non-Executive Director

Mr McNamara joined the Board in January 2020. He has over 30 years' experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd, Microbio Pty Ltd, ESN Cleer Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in Avita Medical Ltd, Bioxyne Ltd, and Saluda Medical Pty Ltd. Mr McNamara has also served as CIO of BioScience Managers Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.
Dr Gregory (Greg) Collier Non-Executive Chairman,Non-Executive Director Apr 2019

Dr Gregory (Greg) Collier

Non-Executive Chairman,Non-Executive Director

Dr Collier has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. Dr Collier has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has successfully taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a researchbased Company with a market capitalisation of $10 million to a Company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now subsidiary of Teva Pharmaceuticals Industries Limited) for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
Ms Melanie Jaye Leydin Chief Financial Officer,Company Secretary Dec 2018
Dr Ross Murdoch Non-Executive Director Apr 2015

Dr Ross Murdoch

Non-Executive Director

Dr Murdoch joined Avecho as CEO in January 2015 and was appointed as director in April 2015. He has almost 30 years' experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals (one of the world's leading specialty pharmaceutical companies), based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business and President and COO of Prana Biotechnology Limited based in Australia.
Paul Gavin Chief Executive Officer N/A
Roksan Libinak Chief Operating Officer N/A

Director Transactions

AVE directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/09/21 Gregory (Greg) Collier Expiry 2,250,000 $0.018 $40,500 Options expired
31/05/21 Matthew McNamara Issued 3,993,644 $0.019 $75,879 Issue of options
31/05/21 Ross Murdoch Issued 3,993,644 $0.019 $75,879 Issue of options
31/05/21 Gregory (Greg) Collier Issued 5,990,465 $0.019 $113,818 Issue of options

Director Interests

The current holdings of AVE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Matthew McNamara 25/02/2022 N/A N/A 3,993,644 N/A
Ross Murdoch 25/02/2022 1,666,667 N/A 3,993,644 N/A
Gregory (Greg) Collier 25/02/2022 N/A 2,000,000 5,990,465 N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Feb 3, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Mark Gregory Kerr + Mrs Linda Marie Kerr (Lindmark Inv Staff S/F A/C) 164,684,474 8.96%
Hsbc Custody Nominees (Australia) Limited 105,352,596 5.73%
Rosscope Pty Ltd (Ross Copeland Family A/C) 84,215,363 4.58%
Mark Gregory Kerr (Lindmark Inv Staff S/F A/C) 67,153,797 3.65%
Melbourne Securities Corporation Limited (Horizon 3 Bioteh Fund A/C) 59,345,624 3.23%
BNP Paribas Noms Pty Ltd (DRP) 35,325,418 1.92%
Servbond Pty Limited (Servbond Pty Ltd S/F A/C) 24,000,000 1.31%
Citicorp Nominees Pty Limited 22,934,333 1.25%
ACK Pty Ltd (Markoff Super No 2 A/C) 20,494,147 1.12%
Kazakco Pty Ltd (Kent Family A/C) 20,000,000 1.09%
Mr Tony Domenic Amato 19,500,712 1.06%
Churchcourt Pty Limited 19,162,500 1.04%
Mr Ross Graham Copeland + Mrs Gina Copeland (Publicity Press S/F A/C) 16,868,545 0.92%
Dr Maurice Arthur Trewhella + Mrs Elizabeth Trewhella (Simpetejen Super Fund A/C) 16,000,000 0.87%
Mr Yong Wang 15,539,953 0.85%
Mrs Susan Margaret Chudleigh + Mr John West Chudleigh 15,000,000 0.82%
Mr Gary Dean Shaw 15,000,000 0.82%
BHL Pension Pty Ltd (BHL Pension Fund A/C) 15,000,000 0.82%
Mr Brandon Armon Batagol 13,932,870 0.76%
Gold Road Orient Holdings Pty Ltd 12,500,000 0.68%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 467 878 625 2,428 1,391 5,789

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Mark Gregory KERR 03/02/2022 199,503,526 10.91

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.016 30 June
2020 $0.007 30 June
2019 $0.003 28 June
AVE Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.